Clinical Trial Update: Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating mutation-targeted therapy with sunitinib or everolimus in advanced low- or intermediate-grade neuroendocrine tumors of the GI tract and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Neuroendocrine
• Neuroendocrine Carcinoma
• Neuroendocrine Neoplasms
• Neuroendocrine Tumors

Drugs mentioned

• Everolimus (everolimus)
• Sunitinib (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neuroendocrine Tumors, Neuroendocrine Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2020-09-09